SYS ONLINE
Supplements/Peptide

Tesamorelin (Ref)

GHRH analog approved for HIV-associated visceral adiposity.

Buy

Overview

GHRH analog approved for HIV-associated visceral adiposity.

Natural sources
  • Synthetic peptide manufactured to pharmaceutical or research-grade purity
  • Subcutaneous injection, sublingual, or oral preparation depending on bioavailability
  • Compounded by a licensed pharmacy for clinical use
Common forms
  • Subcutaneous injection
  • Oral or sublingual lozenge
  • Nasal spray
  • Compounded topical

Mechanism of action

Stimulates endogenous GH release via pituitary GHRH receptor.

Pathways
  • · Stimulates endogenous GH release via pituitary GHRH receptor

Effects on the body

Decreases
visceral adipose tissue

Organ system effects

Evidence-based benefits

Reduces visceral adipose tissue

Strong evidence

Potential side effects

Common
  • · Injection site reactions
Rare
    Serious
    • · Hyperglycemia

    Drug interactions

    Prescription medications (general)
    Always disclose Tesamorelin (Ref) use to your prescriber — additive, antagonistic, or pharmacokinetic interactions are possible.
    minor

    Safety & non-supplemental interactions

    Educational summary — always confirm with your clinician or pharmacist before starting, stopping, or combining with prescription therapy.

    Avoid if you are
    • ·Pregnant or breastfeeding (insufficient safety data)
    • ·Children under 18 (unless directed by a clinician)
    Other notes
    • ·Most research peptides are not FDA-approved for human use outside investigational protocols.

    Supplement interactions

    Pairs well with
    • A high-quality multivitamin
      Covers micronutrient cofactors that support most supplement pathways.
    • Omega-3 (EPA/DHA)
      Foundational anti-inflammatory support that complements most regimens.
    Avoid combining with

    No specific avoidances listed.

    Dosing & bioavailability

    Typical dose
    2 mg SC daily (Rx)
    Best form
    Most evidence is based on the subcutaneous injection form.
    Timing
    Consistent daily timing recommended; split larger doses if GI tolerance is a concern.
    With food?
    Either with or without food.

    Where to buy

    Affiliate links — we may earn a commission at no extra cost to you. Amazon code supplementsch-20 is auto-applied at checkout. We don't endorse specific brands; verify third-party testing (USP, NSF, Informed Sport) before purchase.

    Scientific evidence8Show studies
    RCTN Engl J Med · 2007

    Tesamorelin in HIV lipodystrophy

    Falutz J, et al.

    26-week DB-RCT in 412 HIV patients.

    Key findings

    Reduced VAT by ~15% vs placebo.

    Open study
    Systematic reviewPubMed (NLM) · 1970

    PubMed: Tesamorelin (Ref) — Reduces visceral adipose tissue

    Live PubMed search

    Live results for "Tesamorelin (Ref) Reduces visceral adipose tissue" across the PubMed/MEDLINE peer-reviewed index.

    Key findings

    Opens current human and preclinical literature matching Tesamorelin (Ref) and "Reduces visceral adipose tissue". Filter by RCT, meta-analysis, or year on the results page.

    Open study
    Systematic reviewPubMed (NLM) · 1970

    PubMed: Tesamorelin (Ref) — randomized controlled trial

    Live PubMed search

    Live results for "Tesamorelin (Ref) randomized controlled trial" across the PubMed/MEDLINE peer-reviewed index.

    Key findings

    Opens current human and preclinical literature matching Tesamorelin (Ref) and "randomized controlled trial". Filter by RCT, meta-analysis, or year on the results page.

    Open study
    Systematic reviewPubMed (NLM) · 1970

    PubMed: Tesamorelin (Ref) — meta-analysis

    Live PubMed search

    Live results for "Tesamorelin (Ref) meta-analysis" across the PubMed/MEDLINE peer-reviewed index.

    Key findings

    Opens current human and preclinical literature matching Tesamorelin (Ref) and "meta-analysis". Filter by RCT, meta-analysis, or year on the results page.

    Open study
    Systematic reviewPubMed (NLM) · 1970

    PubMed: Tesamorelin (Ref) — pharmacokinetics

    Live PubMed search

    Live results for "Tesamorelin (Ref) pharmacokinetics" across the PubMed/MEDLINE peer-reviewed index.

    Key findings

    Opens current human and preclinical literature matching Tesamorelin (Ref) and "pharmacokinetics". Filter by RCT, meta-analysis, or year on the results page.

    Open study
    Systematic reviewPubMed (NLM) · 1970

    PubMed: Tesamorelin (Ref) — safety adverse events

    Live PubMed search

    Live results for "Tesamorelin (Ref) safety adverse events" across the PubMed/MEDLINE peer-reviewed index.

    Key findings

    Opens current human and preclinical literature matching Tesamorelin (Ref) and "safety adverse events". Filter by RCT, meta-analysis, or year on the results page.

    Open study
    Systematic reviewPubMed (NLM) · 1970

    PubMed: Tesamorelin (Ref) — dose response

    Live PubMed search

    Live results for "Tesamorelin (Ref) dose response" across the PubMed/MEDLINE peer-reviewed index.

    Key findings

    Opens current human and preclinical literature matching Tesamorelin (Ref) and "dose response". Filter by RCT, meta-analysis, or year on the results page.

    Open study
    Systematic reviewGoogle Scholar · 1970

    Google Scholar: Tesamorelin (Ref) — clinical evidence

    Live Scholar search

    Cross-database citation index for Tesamorelin (Ref) as it relates to "clinical evidence".

    Key findings

    Includes preprints, theses, and journal articles. Useful for tracking citation counts and follow-on work.

    Open study
    Educational use only. This profile is not medical advice. Consult a qualified healthcare professional before starting any supplement, especially if you take prescription medication or have a chronic condition.

    Community discussion

    (0 threads)

    Share your experience or read what others have tried. Anecdotes are not medical advice.

    Sign in or create a free account to post or reply.
    Loading discussion…